daprodustat (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Anemia of Chronic Kidney Disease

Pending FDA approval for treatment of anemia of chronic kidney disease

Next:

Pharmacology

Mechanism of Action

Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilizes hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anemia, similar to the physiological effects that occur in the human body at high altitude

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.